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The role of Propionibacterium acnes in acne and in a wide range of inflammatory diseases is well established. However, P. acnes is
also responsible for infections involving implants. Prolonged aerobic and anaerobic agar cultures for 14 days and broth cultures
increase the detection rate. In this paper, we review the pathogenic role of P. acnes in implant-associated infections such as
prosthetic joints, cardiac devices, breast implants, intraocular lenses, neurosurgical devices, and spine implants. The management
of severe infections caused by P. acnes involves a combination of antimicrobial and surgical treatment (often removal of the device).
Intravenous penicillin G and ceftriaxone are the first choice for serious infections, with vancomycin and daptomycin as alternatives,
and amoxicillin, rifampicin, clindamycin, tetracycline, and levofloxacin for oral treatment. Sonication of explanted prosthetic
material improves the diagnosis of implant-associated infections. Molecular methods may further increase the sensitivity of P.
acnes detection. Coating of implants with antimicrobial substances could avoid or limit colonization of the surface and thereby
reduce the risk of biofilm formation during severe infections. Our understanding of the role of P. acnes in human diseases will
likely continue to increase as new associations and pathogenic mechanisms are discovered.
1. Introduction
Propionibacterium acnes is part of the normal human micro-
biota [1, 2]. This bacterium is usually responsible for late
chronic infections but, exceptionally, could produce acute
infections, mainly related to any device. The P. acnes genome
encodes diverse virulent factors which confer a pathogenic
potential to this bacterium [3].
The role of P. acnes in the pathogenesis of acne is
known for decades. Numerous reports reveal that P. acnes
has been also associated with chronic prostatitis lead-
ing to prostate cancer [4], chronic recurrent multifocal
osteomyelitis (CRMO) and synovitis-pustulosis-hyperostosis
and osteitis (SAPHO) syndrome [5], sarcoidosis [6, 7], and
sciatica [8]. More recently, this microorganism has been
recognized as the cause of various types of implant-associated
infections, including breast implants [9, 10], neurosurgical
shunts [11], cardiovascular devices [12], ocular implants [13],
internal fracture fixation devices, spinal hardware [14], and
prosthetic joints [15] (Figure 1).
2. Microbiology
P. acnes is an anaerobic-aerotolerant diphtheroid-like Gram-
positive bacillus that resides in pilosebaceous follicles of the
skin (Figure 2) [1], and is also found in the conjunctiva [2],
oral cavity [2], intestinal tract [16], and external ear canal [1].
The P. acnes genome encodes all key components of oxida-
tive phosphorylation (NADH dehydrogenase/complex I,
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Figure 1: Diversity of implant-associated infections caused by P. acnes.
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Figure 2: Scheme of a normal pilosebaceus unit of human skin.
The hair, sebum, and keratinocytes that fill the narrow follicle may
produce a plug. The mixture of oil and cells desquamate allows
P. acnes to grow in the plugged follicles, producing chemicals
and enzymes that attract host immune cells causing inflammation.
Source: National Institutes of Health (NIH), Department of Health
and Human Services.
cytochrome c reductase, cytochrome c oxidase, and FOF1-
typeATP synthase). In addition, it also possesses the genes for
the cytochrome d oxidase, which ensures growth in different
conditions [3, 17, 18].Therefore, P. acnes can tolerate exposure
to oxygen for several hours and is capable in vitro to survive
under anaerobic conditions for up to 8 months [19]. The
latter observation suggests that P. acnes can also survive for
a prolonged period in human tissues with low oxidation
potential [18, 19].
Despite its oxygen-tolerant characteristics, P. acnes is not
reliably detected by aerobic culture due its slow growth [20].
The optimal temperature for growth is 37∘C. To increase the
detection, prolonged aerobic and anaerobic agar cultures to
14 days and inoculation into thioglycollate broth should be
routinely performed [20–22]. In particular, the low redox
potential of enriched thioglycollate broth supports growth of
P. acnes. Importantly, thioglycollate broth should be routinely
subcultured on agar plates despite the absence of visible tur-
bidity of the broth medium [23]. However, a positive culture
with P. acnes should be interpretedwith caution. For example,
in case of recovery in broth cultures only or from only one of
several tissue samples, additional criteria of infection (such as
clinical signs, positive histopathology, or molecular tests) are
required [23, 24]. In addition, P. acnes should be considered
as pathogen in chronic or persistent low-grade implant-
associated infections without positive cultures, in which this
pathogen is probably underrecognized and underestimated
[25, 26].
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According to serological agglutination tests and cell wall
carbohydrate analysis, P. acnes can be classified into two
different phylotypes (type I and II) [27, 28]. By sequence
analysis of two genes, a nonribosomal housekeeping gene
(recA) and a gene encoding a putative hemolysin/cytotoxin
(tly gene), further discrimination into phylogenetically dis-
tinct clusters (type IA, IB, IC, II, and III) is possible [29].
Recently, MALDI-TOF Mass Spectrometry seems to be a
useful tool for rapid identification and typing of P. acnes [30].
Several genes in the P. acnes genome encode different virulent
factors such as hemolysins, CAMP factors, lipases, esterases,
surface-associated proteins, or cellular factor with antigenic
potential [3, 31]. P. acnes also encodes genes with poly (C)/(T)
stretches. Such variations seem to be involved in phase
variation, an adaptation strategy to evade immune responses
and degradation [3]. However, from infected prosthesis type
IB strains were more frequently isolated than type IA.
Several researchers investigated the association between
the pathogenicity of different P. acnes phylotypes and their
clinical significance [3, 32, 33]. No clear association between
phylotypes and infection/colonization has been found. Nev-
ertheless, some phylotypes have been described more fre-
quently in specific infections than others. For instance, in
a recent study on shoulder implant infections, P. acnes was
isolated only in male patients, suggesting that host factors
could predispose for infection with this microorganism [34].
Moreover, P. acnes type I was predominant in all types of
orthopedic implants, except in prosthetic hip joints, in which
type I and type II showed equal frequency.
Genomic variation among individual types seems to
be low, but there are key differences in genomic island-
like regions encoding a variety of virulence-associated traits
[32]. Biofilm formation may be one virulence determinant
facilitating implant-associated infections [3]. The genome
sequence has revealed three clusters of genes that encode
enzymes involved in extracellular polysaccharide biosynthe-
sis and adhesion proteins required for biofilm production [3].
3. Implant-Associated Infections
3.1. Periprosthetic Joint Infection. The pathogenesis of peri-
prosthetic joint infection (PJI) is related to microorganisms
growing in biofilms, rendering these infections difficult to
diagnose and to eradicate [35–37]. PJI can be caused by
direct contamination of the surgical wound and the implant
during surgery (i.e., perioperative infection), by spreading
from a remote infectious focus (i.e., hematogenous infection)
or by extension from a neighbored focus or penetrating
injury (i.e., contiguous infection) [37]. Staphylococci are
the most commonly isolated organisms (≈50%), followed
by streptococci (≈10%), enterococci (≈10%), and Gram-
negative bacilli (≈10%) [37, 38]. The frequency of P. acnes
is reported in approximately 10% of PJI, but its frequency is
most likely underestimated due to short incubation times in
many routine laboratories and its growth being considered
as contamination [23]. P. acnes is most frequently associated
with shoulder PJI and spine implant-associated infections
due to a high concentration of sebaceous follicles at these sites
[15, 39].
Low-grade infections are typically manifested 3 to 24
months after implantation, or occasionally up to 36months or
longer. As P. acnes belongs to the normal skin microbiota, the
significance of its growth may be difficult to determine [23].
In low-grade infection, the values of systemic inflammatory
biomarkers, such as C-reactive protein (CRP), are often nor-
mal [40–42]. Similarly, periprosthetic tissue histopathology
may show no acute or only chronic inflammation, reflecting
the low virulence and lowbacterial burden ofP. acnes [40, 43].
A combination of various preoperative and intraoperative
tests is needed for accurate diagnosis of low-grade infection of
prosthetic joints [23, 44]. When PJI is diagnosed, a two-stage
exchange is usually performed since the prosthesis is typically
loosened and retention is not possible anymore. A short
interval between prosthesis explantation and reimplantation
(i.e., 2-3 weeks) is increasingly used, if P. acnes is susceptible
to rifampin, the key antibiotic against biofilms [45].
Current diagnosticmethods for PJI such as periprosthetic
tissue cultures have limited sensitivity, with 10–20% false-
negative cultures [46]. Recently, molecular techniques have
been developed to increase the sensitivity of PJI detection,
but P. acnes specific primers are not included in such assays
[46, 47].
Several investigators suggested that some cases of pros-
thesis failure considered as aseptic may actually be of infec-
tious etiology [48–50]. However, the survival time for joint
prosthesis was not shorter when P. acnes was cultured in
aseptic loosening cases (about 20% of cases), suggesting that
this microorganism may have another, yet unknown, role in
such cases [51].
3.2. Cardiac Device Infection. P. acnes infective endocarditis
remains rare, although its prevalence is probably underes-
timated due to diagnostic difficulties [25]. Infection mostly
involves prosthetic heart valves [25], annuloplasty rings [52],
and pacemaker/ICD leads [53]. Bacteremia or skin wounds
are the most frequent port of entry of microorganisms [12]. P.
acnes infective endocarditis often develops on valve prosthe-
ses and embolisms are common. To the best of our knowl-
edge, less than 50 cases of infective endocarditis have been
described on prosthetic heart valves, usually the aortic valve
prosthesis [25]. Due to subtle symptoms and slow growth of
the microorganism, the diagnosis is often late, when valvular
and peri-valvular destruction is significant [54]. Antibiotic
therapy and surgical intervention with change of the valve are
typically needed, and the mortality is high (15–27%) [12, 55].
The diagnosis of P. acnes infective endocarditis using Duke
criteria is challenging [56], since echocardiography can be
normal and the dysfunction progresses slowly over weeks and
months leading to cardiac insufficiency [25, 57, 58]. Fever
appears only in approximately 25% of these patients, and
the incidence of neurologic symptoms is higher than that in
general complication of infective endocarditis [25, 55].
3.3. Breast Implant Infection. Breast implants are increasingly
used for aesthetic reasons or in patients after mastectomy
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[59, 60]. Infection occurs in 1.1% to 2.5% after aesthetic breast
augmentation and up to 35% after breast implant reconstruc-
tion followingmastectomy [61].These infections are typically
caused by bacterial skin flora, such as Staphylococcus aureus
and coagulase-negative staphylococci [62]. Acute infections
associated with breast implants usually occur during the first
month after implantation and are frequently associated with
fever, acute pain, andmarked breast erythema. In some cases,
P. acnes could be recovered alone or in combination with
staphylococci. Late infections are rare and often associated
with bacteremia or an invasive procedure at a location other
than the breasts. Risk factors for breast implant infection
are breast reconstruction after mastectomy and radiotherapy
[62]. Surgical removal of the implant is mandatory in most
cases by two-step procedure [63].
Developments in chemistry have improved the material
characteristics of breast implants and reduced capsular con-
tracture [64]. However, the incidence of capsular contracture
after breast implant surgery is up to 30% and its etiology
remains unclear [65, 66]. The modified Baker classification
of capsular contracture includes degree I to IV [67]. Possible
explanations for this important complication include chem-
ical interference of the implant in the surrounding tissues,
mechanical impact by the anatomical position of the implant,
and the effect of bacteria growing in biofilms on the implant
surface [68]. Another possible cause of capsular contracture
is the presence of bacteria growing as biofilm on the surface,
which may cause persistent low-grade inflammation of the
surrounding tissue, leading to formation of capsular fibrosis
and subsequent contracture [69, 70]. A significant correlation
between the degree of capsular contracture and the presence
of biofilm on breast implants was demonstrated by several
authors, especially when using a sonication technique [9, 10,
71]. In a recent study, 112 breast implants were sonicated. Fifty
two of them had a positive sonication fluid culture (46%).
Amongpositive sonication fluid cultures,P. acneswas isolated
in most cases (54%). P. acnes seems to have a role especially
in Baker grade IV (Figure 3) [72]. Its origin is most likely the
patient skin or colonized mammary ducts at the incision site
[62].
3.4. Infections of Intraocular Lenses. Infectious endophthal-
mitis is the most devastating complication of intraocular
surgery. The incidence of infection after cataract surgery
and posterior chamber lens implantation is low, reported
from 0.07 to 0.33% [73]. Bacterial biofilm is produced in
the intraocular lenses by microorganisms which adhere
to the lenses [74]. Postoperative endophthalmitis can be
classified into acute and delayed infection. While acute
endophthalmitis usually occurs soon after surgery and is
caused by S. aureus, Streptococcus spp., or coagulase-negative
staphylococci, delayed infections appear from months to
years after surgery and are predominantly caused by low-
virulent microorganism such as P. acnes, Actinomyces spp.
or Corynebacterium spp. [75]. Endophthalmitis diagnosis
is based on the appearance of ocular signs and symptoms
combined with microscopic and microbiologic examination
of the intraocular samples [76]. The most characteristic
manifestation of delayed postoperative endophthalmitis is
70
60
50
40
30
20
10
0
Po
sit
iv
e s
on
ic
at
io
n 
cu
ltu
re
 (%
)
Grade I Grade II Grade III Grade IV
n = 11 n = 10 n = 23 n = 45
Degree of capsular contracture (Baker classification)
Figure 3: High correlation between the degree of capsular contrac-
ture and sonication culture of 89 removed breast implants without
clinical signs of infection (𝑃 for trend <0.001). Reproduced with
permission from Rieger et al. [71].
the appearance of white plaques on the lens capsule or the
intraocular lens associated with chronic, recurring intraoc-
ular infection [75]. Cultures of vitreous biopsy sample often
fail to detect the causative microorganisms due to their low
number and low virulence in delayed postoperative endoph-
thalmitis [76]. Molecular diagnostic techniques by PCR have
several advantages, although they are not always routinely
implemented [75]. The surgical approach, especially in P.
acnes cases, involves a pars planavitrectomy and may include
a selective posterior capsulectomy with intraocular injection
of antibiotics or a total capsulectomy with intravitreous
antibiotics as well as extraction of the intraocular lens [77].
3.5. Neurosurgical Shunt Infection. P. acnes is increasingly
documented in neurosurgical infection involving internal
cerebrospinal fluid (CSF) shunts and external ventricular
drains (EVD). Internal shunts generally transfer CSF into the
peritoneal cavity (ventriculo-peritoneal shunts) but can be
placed also into the right atrium (ventriculo-atrial shunts) or
rarely in the pleural space, ureter, gall bladder, or fallopian
tube [78]. Internal CSF shunt infection constitutes a serious
complication with considerable mortality and morbidity,
especially in pediatric patients [79]. The infection rate ranges
from 1.5 to 38% [80].
Shunt infections can be classified as early or late depend-
ing on whether these infections occur before or after the first
year of surgery [79]. Early shunt infections are mainly caused
by skin microorganisms introduced during surgery [81]. Late
shunt infections are less frequent, <1% annually [82], and
usually related to peritonitis (generally due to appendicitis)
or to hematogenous sources from secondary infections [83].
Clinical manifestations include fever, shunt malfunction,
malaise, poor feeding, peritoneal signs, localized abdominal
abscess/CSF collection, and wound breakdown [83, 84]. In
the absence of fever, differentiation between shunt dysfunc-
tion and shunt infection is difficult [20, 85].Moreover, allergic
reactions to shunt material such as silicone or ethylene oxide
may also mimic shunt infections [86, 87]. A young age at
the time of initial shunt placement and a short time interval
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from previous surgical revision are risk factors associated
with shunt infection [88]. In general, coagulase-negative
staphylococci, S. aureus, and P. acnes are the most common
infectingmicroorganisms implicated in shunt infections [89].
Although P. acnes shunt infections are mainly triggered
by bacterial contamination from the skin during surgery,
symptoms may occur weeks to years after shunt placement
or manipulation [20].
Shunt infection is diagnosed based on the combination
of clinical signs, CSF cell count and CSF culture sampled
through a reservoir tap or lumbar puncture [89]. Differentia-
tion between true infections and contaminations remains dif-
ficult. Visualization of microorganisms after Gram straining
of CSF is often not possible, and cellular and chemical fluid
changes may be subtle [20]. P. acnes shunt infections typically
are indolent and present with normal serum CRP levels [90].
Patients present with low initial leukocyte count, percentage
of neutrophils, high peak of eosinophil percentage, andminor
changes in CSF including glucose or protein levels [20, 91].
However, CSF eosinophilia could be associatedwith reactions
to foreign substances, particles or blood, and obstruction of
tubing but also by infection caused by coagulase-negative
staphylococci [92]. Therefore, culture of CSF remains the
most valuable tool for the diagnosis of shunt-associated
infection [20].
Themost effective treatment for P. acnes shunt infection is
shunt removal, temporary placement of an external ventric-
ular drainage or ventricular taps (if needed), and treatment
with high-dose intravenous penicillin G [20, 93]. Retention
of the distal shunt part often leads to relapse of infection
and shunt failure [94]. A new shunt should be placed when
CSF becomes sterile [94]. Antibiotic-impregnated shunt
systems were introduced to prevent shunt infection [80].
Shunt catheters can be impregnated with antibiotics (often
rifampicin or clindamycin). By using these catheters with
antibiotics, there is a risk of an increase in the rate of antibiotic
resistance rate due to selective pressure. In a recent study, the
incidence of CSF shunt infection was lower in patients with
antibiotic-impregnated shunt systems compared with those
without [95].
External ventricular drains (EVDs) are used in acute
hydrocephalus to prevent further brain damage due to
high CSF pressure. The rate of external ventricular drains-
associated infection ranges from 5 to 22% in high-risk
patients [96–98]. Factors associated with increased risk of
infection are intraventricular or subarachnoid hemorrhage,
cranial fracture with CSF leakage, and catheter irrigation
[96, 99–102]. Although several studies demonstrated that
prolonged external ventricular drains-indwelling time (>3 to
5 days) constitute a risk factor for external ventricular drains-
associated infection [98, 103–106], it remains unclear whether
a regular external ventricular drains exchange can reduce
the infection risk [99, 107–110]. EVD-associated infection
may occur up to 10 days after removal of EVD. Clinical
signs and symptoms of external ventricular drains-associated
infections are nonspecific, such as fever and headache, and
often overlap with signs and symptoms of the underlying
neurosurgical condition. In addition, CSF parameters may
vary widely and none has been shown to be predictive for
infection, nor cutoff values have been established [96, 99,
111, 112]. A positive Gram stain or CSF culture are highly
specific for external ventricular drains-associated infection
but not very sensitive [113, 114]. Cultures of the external
ventricular drains tips may increase the sensitivity, especially
when the removed catheter is sonicated.Most authors suggest
performing a complete CSF diagnostic workup if EVD-
associated infection is suspected, including CSF leukocyte
count and differential, as well as CSF Gram stain and culture
[104, 115, 116]. In a recent study, although most commonly
isolated organisms causing EVD-associated infection were
coagulase-negative staphylococci (63%), P. acnes represented
15% of the cases [117].
3.6. Spine Implant Infection. The rate of infection after spinal
surgery is low, about 0.2%; however, this rate increases up to
12% when instrumentation is used [118–120]. Nevertheless,
the microbiologic diagnosis of spinal implant infection can
be challenging. Spinal implant infections can be classified
as early or late depending on whether the infection occurs
before or after the first month of surgery [121]. Although
P. acnes and S. epidermidis are the most common bac-
terial causes of late postoperative infection [39], P. acnes
is also related to 3–50% of early postoperative infections
[121, 122]. Clinical manifestations of spine implant infection
are usually nonspecific like back pain and paravertebral
spasms [123]. Other common symptoms include drainage
and localized swelling or fullness along the length of the
incision [119, 120]. Fever is infrequently reported [123].
Inflammatory biomarkers such as CRP, ESR, andWBCvalues
are unreliable as diagnostic markers of low grade spinal
implant infections because they may be within the normal
range [121]. Presence of infection is usually confirmed by
radiographic and microbiological findings. Magnetic reso-
nance imaging (MRI) is considered as the best diagnostic
imaging approach (when no device is present) to detect spinal
infections [123]. The causative pathogen can be isolated by
culturing samples taken by biopsy or peri-implant tissues
[124]. Implant sonication is more sensitive than peri-implant
tissue culture [39]. The management of spinal implant infec-
tion is controversial. While some authors recommend serial
debridement surgeries with implant retention [125, 126],
others advocate implant removal [127]. Contraindications to
hardware removal are stated in cases where fusion has not yet
taken place [128]. Improved infection-free interval has been
reported using long-term oral suppressive antibiotics [125].
4. Treatment
The management of severe infections caused by P. acnes
involves a combination of intravenous antimicrobial agents
and surgical procedures (e.g., removal of the device and/or
debridement of the surgical site). For serious infections,
penicillin G and ceftriaxone are considered antibiotics of first
choice [129], with vancomycin and daptomycin as alterna-
tives in case of 𝛽-lactam allergy or antimicrobial resistance.
Clindamycin, tetracycline, and levofloxacin are oral alterna-
tives for nonserious infections, mostly skin diseases [130].
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Rifampin is considered active against P. acnes biofilm [131].
Importantly, P. acnes is intrinsically resistant to metronida-
zole and fosfomycin. Aminoglycosides have generally weak
activity and should not be used in the treatment of P. acnes
infections.
5. Outlook
Sonication of explanted prosthetic material has shown to
be more sensitive than conventional microbiological culture
in the diagnosis of foreign body infections, especially in
orthopedic prosthesis, breast implant, and cardiac devices
[10, 132, 133]. Formation of P. acnes biofilms on implants
highlights the importance of vortexing/sonication to detach
the microorganism prior to culture [134, 135]. Therefore,
sonication procedure should be applied routinely to all types
of implants in order to improve the diagnosis of implant-
associated infections caused by P. acnes. Also, disruption of
the periprosthetic tissue samples improves the diagnosis as
adherent cells are detached and removed [136]. Otherwise,
new molecular methods for implant-associated infections
may be developed in the future to provide rapid and sen-
sitive detection of P. acnes. Moreover, these techniques are
not affected by previously administered antibiotics. These
new techniques would also be able to detect virulence or
antibiotic resistance genes and specificmRNA to differentiate
active from latent or previous infection. Coating of implants
with antimicrobial substances may avoid colonization of the
surface by microorganisms and reduce the risk of biofilm
formation and clinical infections. Our understanding of the
role of P. acnes in human diseases will likely continue to
increase as new associations and pathogenicmechanismswill
be discovered.
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